relugolix + atorvastatin

This is a combination of **relugolix (TAK-385)** and **atorvastatin**. Relugolix is an oral, non-peptide GnRH (gonadotropin-releasing hormone) antagonist that rapidly lowers testosterone levels by competitively blocking the GnRH receptor, suppressing LH (luteinizing hormone), FSH (follicle-stimulating hormone), and ultimately testosterone production. Atorvastatin is a small molecule statin used to inhibit HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, thereby reducing cholesterol levels. The combination as used in research is not an approved fixed-drug product or branded combination; rather, atorvastatin has been investigated for its potential interaction with relugolix pharmacokinetics in healthy subjects. There is no established clinical indication for the fixed combination, but relugolix is primarily developed for advanced prostate cancer and other hormone-dependent conditions, while atorvastatin is used for hypercholesterolemia and cardiovascular risk reduction[1][2][3][7].